Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study

Published:2017-03-20 Issue:3 Volume:12 Page:e0174005
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Hegen Harald^ORCID,Auer Michael,Bsteh Gabriel,Di Pauli Franziska,Plavina Tatiana,Walde Janette,Deisenhammer Florian,Berger Thomas

Funder

Biogen

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference22 articles.

1. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;CH Polman,2006

2. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis;CS Tan,2010

3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;G Bloomgren,2012

4. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort;T Olsson,2013

5. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort;AK Trampe,2012

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis;Multiple Sclerosis Journal;2024-02-26

2. Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-12

3. Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2022-07

4. JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies;Journal of Clinical Medicine;2021-05-06

5. High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients;Therapeutic Advances in Neurological Disorders;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3